Viridian Therapeutics Inc (NASDAQ: VRDN) on Friday, soared 3.29% from the previous trading day, before settling in for the closing price of $21.57. Within the past 52 weeks, VRDN’s price has moved between $11.40 and $25.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -12.71% over the last five years. The company achieved an average annual earnings per share of 27.08%. With a float of $67.61 million, this company’s outstanding shares have now reached $76.36 million.
The firm has a total of 96 workers. Let’s measure their productivity. In terms of profitability, gross margin is -2268.4%, operating margin of -87078.47%, and the pretax margin is -79185.76%.
Viridian Therapeutics Inc (VRDN) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Viridian Therapeutics Inc is 11.45%, while institutional ownership is 82.61%. The most recent insider transaction that took place on Sep 27 ’24, was worth 117,050. In this transaction Chief Operating Officer of this company bought 5,000 shares at a rate of $23.41, taking the stock ownership to the 6,000 shares. Before that another transaction happened on Sep 27 ’24, when Company’s President and CEO bought 21,400 for $23.33, making the entire transaction worth $499,262. This insider now owns 21,400 shares in total.
Viridian Therapeutics Inc (VRDN) Earnings and Forecasts
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -1.09 earnings per share (EPS) for the period topping the consensus outlook (set at -1.27) by 0.18. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 27.08% per share during the next fiscal year.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
Viridian Therapeutics Inc (VRDN) is currently performing well based on its current performance indicators. A quick ratio of 15.82 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6059.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.25, a number that is poised to hit -1.06 in the next quarter and is forecasted to reach -4.18 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Analysing the last 5-days average volume posted by the [Viridian Therapeutics Inc, VRDN], we can find that recorded value of 0.68 million was lower than the volume posted last year of 1.11 million. As of the previous 9 days, the stock’s Stochastic %D was 8.96%. Additionally, its Average True Range was 1.13.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 77.31%, which indicates a significant increase from 19.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.61% in the past 14 days, which was lower than the 70.80% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.91, while its 200-day Moving Average is $16.98. Now, the first resistance to watch is $22.65. This is followed by the second major resistance level at $23.01. The third major resistance level sits at $23.49. If the price goes on to break the first support level at $21.81, it is likely to go to the next support level at $21.33. Should the price break the second support level, the third support level stands at $20.97.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
Market capitalization of the company is 1.76 billion based on 63,890K outstanding shares. Right now, sales total 310 K and income totals -237,730 K. The company made 70 K in profit during its latest quarter, and -64,990 K in sales during its previous quarter.
